Table 3 New medication prescriptions during baseline and post-acute phasesa in the overall population (N = 3792)
USC medication class description | Baseline phase, n (%) | Post-acute phase, n (%) | Change from baseline to post-acute phase, Δ (% change) |
|---|---|---|---|
Hormones | 228 (6.0) | 658 (17.4) | 430 (188.6) |
Vascular agents | 130 (3.4) | 277 (7.3) | 147 (113.1) |
Musculoskeletal | 153 (4.0) | 249 (6.6) | 96 (62.7) |
Antihyperlipidemic agents | 148 (3.9) | 239 (6.3) | 91 (61.5) |
Neurological/neuromuscular disorders | 118 (3.1) | 190 (5.1) | 72 (61.0) |
Analgesics | 302 (8.0) | 485 (12.8) | 183 (60.6) |
Psychotherapeutic drugs | 354 (9.3) | 560 (14.8) | 206 (58.2) |
Gastrointestinal | 191 (5.0) | 285 (7.5) | 94 (49.2) |
Ophthalmic preparations | 112 (3.0) | 157 (4.1) | 45 (40.2) |
Genitourinary | 168 (4.4) | 235 (6.2) | 67 (39.9) |
Antinauseants | 162 (4.3) | 213 (5.6) | 51 (31.5) |
Antiarthritics | 381 (10.0) | 492 (13.0) | 111 (29.1) |
Dermatologicals | 139 (3.7) | 171 (4.5) | 32 (23.0) |
Thyroid therapy | 105 (2.8) | 129 (3.4) | 24 (22.9) |
Anti-fungal agents | 206 (5.4) | 236 (6.2) | 30 (14.6) |
Contraceptives | 278 (7.3) | 281 (7.4) | 3 (1.1) |
Anti-infectives, systemic | 1020 (26.9) | 928 (24.5) | –92 (–9.0) |
Respiratory therapy | 469 (12.4) | 369 (9.7) | –100 (–21.3) |
Antivirals | 287 (7.6) | 147 (3.9) | –140 (–48.8) |
Cough/cold/flu preparations | 302 (8.0) | 80 (2.1) | –222 (–73.5) |